Perspectives on interferon-alpha in the treatment of Polycythemia vera and related Myeloproliferative neoplasms: minimal residual disease and cure?

Genetic variation in IL28B (IFNL3 ) and response to interferon-alpha treatment in myeloproliferative neoplasms

(2018) Marie Lindgren et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses

(2018) Tsewang Tashi et al.   LEUKEMIA

Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase

(2018) Lise-Marie Mollard et al.   LEUKEMIA & LYMPHOMA

Recent advances in the genomics and therapy of BCR/ABL1 -positive and -negative chronic myeloproliferative neoplasms

(2018) Tariq I. Mughal et al.   LEUKEMIA RESEARCH

Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

(2018) Alessandro Prestipino et al.   Science Translational Medicine

Cancer immune therapy for myeloid malignancies: present and future

(2018) Morten Orebo Holmström et al.   Seminars in Immunopathology

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

(2018) Stine Ulrik Mikkelsen et al.   Cancer Medicine

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

(2018) Morten Orebo Holmström et al.   OncoImmunology

Spontaneous T-cell responses against Arginase-1 in chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation

(2018) Mia Aaboe Jørgensen et al.   OncoImmunology

The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies

(2018) Brianna Craver et al.   Cancers

Inflammation and myeloproliferative neoplasms

(2017) Federico Lussana et al.   JOURNAL OF AUTOIMMUNITY

Can pegylated interferon improve the outcome of polycythemia vera patients?

(2017) Elena Crisà et al.   Journal of Hematology & Oncology

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

(2017) M O Holmström et al.   LEUKEMIA

Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial

(2017) K. Gowin et al.   LEUKEMIA RESEARCH

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

(2017) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

(2017) Mads Emil Bjørn et al.   Expert Review of Hematology

Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms

(2017) Marie Bak et al.   JAMA Ophthalmology

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial

(2017) Lucia Masarova et al.   Lancet Haematology

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

(2017) Morten Orebo Holmström et al.   OncoImmunology

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development

(2017) Morten Andersen et al.   PLoS One

Activated Stat-3 in Melanoma

(2017) Jane L. Messina et al.   Cancer Control

Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy

(2016) Caitlin O’Neill et al.   ANNALS OF HEMATOLOGY

Beyond tyrosine kinase inhibitors: Combinations and other agents

(2016) Emilie Cayssials et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms

(2016) Iben Onsberg Hansen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

(2016) M O Holmström et al.   LEUKEMIA

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms

(2016) M O Holmström et al.   LEUKEMIA

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

(2016) S Koschmieder et al.   LEUKEMIA

The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms

(2016) Vibe Skov et al.   LEUKEMIA & LYMPHOMA

Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms

(2016) Anders Lindholm Sørensen et al.   LEUKEMIA RESEARCH

Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera

(2016) S. Farmer et al.   OSTEOPOROSIS INTERNATIONAL

Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor Microenvironment

(2016) Xinfeng Chen et al.   Oxidative Medicine and Cellular Longevity

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment

(2016) Lasse Kjær et al.   PLoS One

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b

(2015) Nicole C.C. Them et al.   AMERICAN JOURNAL OF HEMATOLOGY

The interferon-alpha revival in CML

(2015) Moshe Talpaz et al.   ANNALS OF HEMATOLOGY

Clinical and molecular response to interferon-  therapy in essential thrombocythemia patients with CALR mutations

(2015) E. Verger et al.   BLOOD

Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera

(2015) H. Gisslinger et al.   BLOOD

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera

(2015) Caroline H. Riley et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis

(2015) Hans Carl Hasselbalch   EUROPEAN JOURNAL OF HAEMATOLOGY

Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells

(2015) Katherine Y. King et al.   EXPERIMENTAL HEMATOLOGY

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone

(2015) J-J Kiladjian et al.   LEUKEMIA

Smoking as a contributing factor for development of polycythemia vera and related neoplasms

(2015) Hans Carl Hasselbalch   LEUKEMIA RESEARCH

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development

(2015) Holly L. Geyer et al.   MEDIATORS OF INFLAMMATION

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms

(2015) Mads Emil Bjørn et al.   MEDIATORS OF INFLAMMATION

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives

(2015) Hans Carl Hasselbalch et al.   MEDIATORS OF INFLAMMATION

Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response

(2015) Marco Pizzi et al.   MODERN PATHOLOGY

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

(2015) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treating Myeloproliferation — On Target or Off?

(2015) Mary Armanios et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Mutation Order on Myeloproliferative Neoplasms

(2015) Christina A. Ortmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

(2015) Gabriela M. Baerlocher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?

(2015) Hans Carl Hasselbalch et al.   Expert Review of Hematology

Bone morbidity in chronic myeloproliferative neoplasms

(2015) Sarah Farmer et al.   Expert Review of Hematology

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator

(2014) T. Kameda et al.   BLOOD

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

(2014) M. Cazzola et al.   BLOOD

Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis

(2014) Helna Pettersson et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Expansion of circulating CD56brightnatural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α

(2014) Caroline H. Riley et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons

(2014) Eric M. Pietras et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms

(2014) Alexander Sidelmann Christensen et al.   LEUKEMIA RESEARCH

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation

(2014) Bin-Tao Huang et al.   LEUKEMIA RESEARCH

The platelet–cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?

(2014) Hans Carl Hasselbalch   LEUKEMIA RESEARCH

Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression

(2014) Hans Carl Hasselbalch et al.   PLoS One

Antisense Oligonucleotide Therapies

(2014) Kendall S. Frazier   TOXICOLOGIC PATHOLOGY

An Immune Dysregulation in MPN

(2014) Giovanni Barosi   Current Hematologic Malignancy Reports

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-  in a murine model of polycythemia vera

(2013) A. Mullally et al.   BLOOD

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN 

(2013) S. Hasan et al.   BLOOD

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon  -2a

(2013) A. Quintas-Cardama et al.   BLOOD

Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study

(2013) Sarah Farmer et al.   BRITISH JOURNAL OF HAEMATOLOGY

The role of cytokines in the initiation and progression of myelofibrosis

(2013) Hans C. Hasselbalch   CYTOKINE & GROWTH FACTOR REVIEWS

Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms

(2013) Brady L. Stein et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression

(2013) C Marty et al.   LEUKEMIA

Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis

(2013) Vibe Skov et al.   LEUKEMIA & LYMPHOMA

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

(2013) Thomas Stauffer Larsen et al.   LEUKEMIA RESEARCH

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

(2013) Richard T Silver et al.   Expert Review of Hematology

Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

(2012) H. C. Hasselbalch   BLOOD

Demand-adapted regulation of early hematopoiesis in infection and inflammation

(2012) H. Takizawa et al.   BLOOD

Diagnostic value ofJAK2V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population

(2012) Camilla Nielsen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Interferon alpha for Treatment of Chronic Myeloid Leukemia

(2012) Bengt Simonsson et al.   CURRENT DRUG TARGETS

Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives

(2012) Hans Carl Hasselbalch et al.   CURRENT DRUG TARGETS

Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis

(2012) Vibe Skov et al.   EXPERIMENTAL HEMATOLOGY

Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance

(2012) Vibe Skov et al.   LEUKEMIA RESEARCH

Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

(2012) Hans Carl Hasselbalch   LEUKEMIA RESEARCH

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

(2012) Masato Sasaki et al.   NATURE

Statin Use and Reduced Cancer-Related Mortality

(2012) Sune F. Nielsen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

(2011) B. Simonsson et al.   BLOOD

New mutations and pathogenesis of myeloproliferative neoplasms

(2011) W. Vainchenker et al.   BLOOD

Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study

(2011) H. Frederiksen et al.   BLOOD

Recombinant interferon-  may retard progression of early primary myelofibrosis: a preliminary report

(2011) R. T. Silver et al.   BLOOD

The renaissance of interferon therapy for the treatment of myeloid malignancies

(2011) J.-J. Kiladjian et al.   BLOOD

Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN- 

(2011) C. H. Riley et al.   BLOOD

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

(2011) Z. Li et al.   BLOOD

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

(2011) Cyril Quivoron et al.   CANCER CELL

Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation

(2011) Kelly Moran-Crusio et al.   CANCER CELL

Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis

(2011) Vibe Skov et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Monocytes link atherosclerosis and cancer

(2011) Mikael J. Pittet et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera

(2011) E. Kuriakose et al.   HAEMATOLOGICA

Interferon-α in acute myeloid leukemia: an old drug revisited

(2011) S Anguille et al.   LEUKEMIA

Dnmt3a is essential for hematopoietic stem cell differentiation

(2011) Grant A Challen et al.   NATURE GENETICS

Inflammatory signaling compromises cell responses to interferon alpha

(2011) W-C HuangFu et al.   ONCOGENE

Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice

(2011) M. Ko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

(2011) Hans Carl Hasselbalch   Expert Review of Hematology

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)

(2010) S. Thepot et al.   BLOOD

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

How does interferon exert its cell growth inhibitory effect?

(2010) Dan Grandér et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells

(2010) J-J Kiladjian et al.   LEUKEMIA

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

(2009) Thomas Stauffer Larsen et al.   Hematology

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis

(2009) R T Silver et al.   LEUKEMIA

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

IFNα activates dormant haematopoietic stem cells in vivo

(2009) Marieke A. G. Essers et al.   NATURE

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

(2008) T. S. Larsen et al.   ANNALS OF HEMATOLOGY

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis

(2008) Veronika Buxhofer-Ausch et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

(2008) J-J Kiladjian et al.   LEUKEMIA

Immunotherapeutic approaches in chronic myelogenous leukemia

(2008) François Guilhot et al.   LEUKEMIA & LYMPHOMA